Premium
Lupus anticoagulant, anticardiolipin antibodies and hepatitis C virus infection in thalassaemia
Author(s) -
Giordano Paola,
Galli Monica,
Del Vecchio Giovanni C.,
Altomare Maria,
Norbis Francesca,
Ruggeri Luisa,
Petronelli Maria,
DE Mattia Domenico
Publication year - 1998
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.1998.00853.x
Subject(s) - medicine , lupus anticoagulant , autoantibody , hepatitis c virus , immunology , antiphospholipid syndrome , antibody , hepatitis c , anticardiolipin antibodies , virus
Anticardiolipin antibodies (ACA) and lupus anticoagulant (LA) have been detected in patients with hepatitis C virus (HCV) infection and have been associated in autoimmune diseases (i.e. systemic lupus erythematosus) with an increased risk of thromboembolic events. Because of the high prevalence of HCV infection and the thrombotic risk described in thalassaemia we decided to investigate the prevalence of ACA and LA in a cohort of 68 thalassaemia patients. We found a high prevalence (34%) of β2‐glycoprotein I independent ACA in our thalassaemia patients which was related to HCV infection. None of patients developed any complications related to antiphospholipid antibodies (APL); therefore the clinical significance of positivity for APL in patients with HCV infection is at present unclear. In conclusion, the results of our study indicate that ACA in the serum of HCV‐infected thalassaemic patients exhibit the characteristics of natural autoantibodies rather than those of the pathogenic autoantibodies that are found in patients with systemic lupus erythematosus.